Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non Operating Income (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Other Non Operating Income readings, the most recent being -$2.0 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 7488.89% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.0 million, a 2365.85% decrease, with the full-year FY2025 number at -$2.0 million, down 2365.85% from a year prior.
  • Other Non Operating Income hit -$2.0 million in Q4 2025 for Fennec Pharmaceuticals, down from -$3000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $17000.0 in Q2 2025 to a low of -$2.0 million in Q4 2025.
  • Median Other Non Operating Income over the past 5 years was -$3000.0 (2022), compared with a mean of -$124294.1.
  • Biggest five-year swings in Other Non Operating Income: surged 400.0% in 2023 and later crashed 7488.89% in 2025.
  • Fennec Pharmaceuticals' Other Non Operating Income stood at -$1000.0 in 2021, then tumbled by 200.0% to -$3000.0 in 2022, then skyrocketed by 166.67% to $2000.0 in 2023, then crashed by 1450.0% to -$27000.0 in 2024, then crashed by 7488.89% to -$2.0 million in 2025.
  • The last three reported values for Other Non Operating Income were -$2.0 million (Q4 2025), -$3000.0 (Q3 2025), and $17000.0 (Q2 2025) per Business Quant data.